Neuromodulation Market and Forecast to 2021

  April 5, 2017    |      Life Sciences    |       1038


New York City, NY, April 5, 2017/24 Market Reports -- The Global market for Neuromodulation is projected to reach more than US$5 Billion by the end of 2021.

Market growth can be attributed to factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by the players. In addition, rapid advances in the field of neuromodulation and development of minimally invasive techniques have greatly expanded the market. High cost of treatment and negative social perception is restraining the growth of neuromodulation market.

Spinal cord stimulation segment dominated the neuromodulation market in 2015. But its market share will dwindle in the forecasting period due to the highest growth rate of deep brain stimulation. It is expected that deep brain stimulation will grasp nearly 20% market share by the year end of 2021.

Chronic Pain is identified as the largest application segment of the neuromodulation market. Urinary and Fecal Incontinence (UFI) is the second leading segment for neuromodulation market. Refractory epilepsy stands at the third spot in 2015. Parkinson’s disease holds the fourth highest share being followed by Gastro paresis. Essential Tremor and Dystonia are the other leading application segment for neuromodulation market.

Neuromodulation Market: Segmentation

Neuromodulation market is classified on the basis of technology, application, company and geography.

Based on Technology, Neuromodulation market can be segmented as follows:

  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Other Technologies

Based on Application, Neuromodulation market can be segmented as follows:

  • Chronic Pain
  • Parkinson’s disease
  • Urinary Fecal Incontinence
  • Refractory Epilepsy
  • Essential Tremor

Based on Company, Neuromodulation market can be segmented as follows:

  • Medtronic
  • Boston Scientific
  • St Jude Medical
  • Liva Nova (Cyberonics)
  • Nevro

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report concludes with the profiles of major players in the global neuromodulation such as Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro. The major market players are evaluated on various parameters such as company overview, product portfolio, and sales analysis of neuromodulation segment from 2010 to 2021. The report also entails major drivers and challenges of neuromodulation market.

Browse Full Report at: - https://www.24marketreports.com/life-sciences/global-neuromodulation-market-research-report-2016